[EN] PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS [FR] COMPOSÉS PYRROLIDINYLIQUE ET PIPÉRIDINYLIQUE UTILES COMME INHIBITEURS DE NHE-1
[EN] PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS [FR] COMPOSÉS PYRROLIDINYLIQUE ET PIPÉRIDINYLIQUE UTILES COMME INHIBITEURS DE NHE-1
[EN] BORON-CONTAINING SMALL MOLECULES<br/>[FR] PETITES MOLÉCULES CONTENANT DU BORE
申请人:ANACOR PHARMACEUTICALS INC
公开号:WO2017151489A1
公开(公告)日:2017-09-08
Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed.
化合物、药物配方和治疗细菌感染的方法被披露。
Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors
申请人:Ackermann Jean
公开号:US20070129544A1
公开(公告)日:2007-06-07
The invention is concerned with novel substituted piperidine derivatives of formula (I)
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
and X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
申请人:BISCHOFF Alexander
公开号:US20090221583A1
公开(公告)日:2009-09-03
The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
申请人:Forest Laboratories Holdings Limited
公开号:US07842696B2
公开(公告)日:2010-11-30
The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
申请人:Bentzien Joerg Martin
公开号:US20110118262A1
公开(公告)日:2011-05-19
Disclosed are compounds of formula (I) and compositions of the present invention which are inhibitors of the sodium proton exchanger isoform-1 (NHE-I). Also disclosed are methods of using and making the same.